* Crinetics Pharmaceuticals Inc CRNX.OQ reported a
quarterly
adjusted loss of 96 cents per share for the quarter ended
September 30, higher than the same quarter last year, when the
company reported EPS of $-1.01. The mean expectation of
thirteen analysts for the quarter was for a loss of 91 cents per
share. Wall Street expected results to range from $-1.03 to -74
cents per share.
* Reported revenue was zero; analysts expected $240.00
thousand.
* Crinetics Pharmaceuticals Inc's reported EPS for the
quarter was
a loss of 96 cents.
* The company reported a quarterly loss of $76.83 million.
* Crinetics Pharmaceuticals Inc shares had risen by 15.0%
this
quarter and gained 65.2% so far this year.
FORECAST CHANGES
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* In the last 30 days, two analysts negatively revised
earnings
estimates
RECOMMENDATIONS
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 13 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."
* The average consensus recommendation for the biotechnology
&
medical research peer group is also "buy"
Wall Street's median 12-month price target for Crinetics
Pharmaceuticals Inc is 70.00
This summary was machine generated from LSEG data November 13 at
02:26 p.m. UTC. All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Sep. 30 2024 -0.91 -0.96 Missed
Jun. 30 2024 -0.86 -0.94 Missed
Mar. 31 2024 -0.81 -0.93 Missed
Dec. 31 2023 -0.86 -0.90 Missed